“We applaud the National Academies of Sciences, Engineering, and Medicine for its recommendations on cancer control in the United States. The report examines the oncology community’s efforts over the past 10 years and lays out a comprehensive path for addressing the complex issues facing the entire cancer care continuum, from government agencies to the individual physician.
“As the report notes, stakeholders in the cancer community must work together to drive innovation and solve big, systemic problems that impede patient access to high-quality care. ASCO is working to fulfill that need in a number of ways.
"We are pursuing technological innovations that complement our scientific discoveries with our CancerLinQ platform, which aggregates and analyzes information from electronic health records across the United States to improve day-to-day patient care. In addition, our Targeted Agent and Profiling Utilization Registry (TAPUR) Study is evaluating new uses for targeted therapies outside of Food and Drug Administration-approved indications in patients with advanced cancer to increase efficiency and reduce duplication in care and research.
“ASCO commends the National Academies of Sciences, Engineering, and Medicine for this important report. We will continue to work across the cancer community to reduce the global burden of cancer through research, education, and promoting high-quality patient care.”
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.